141 related articles for article (PubMed ID: 29210961)
1. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA.
Bever GJ; Kim DJ; Afshar AR; Rubenstein JL; Damato BE
Retin Cases Brief Rep; 2020; 14(2):116-119. PubMed ID: 29210961
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy.
Venkatesh P; Gogia V; Khanduja S; Gupta S; Kumar L; Garg S
J Cancer Res Ther; 2015; 11(3):668. PubMed ID: 26458712
[TBL] [Abstract][Full Text] [Related]
3. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
4. Pathologically Proven Intraocular Infiltration With Adult T-Cell Leukemia/Lymphoma: Two New Cases With Either Vitreous Opacity or Aqueous Hypopyon and Literature Review of 16 Cases.
Matsuo T; Shimizu T; Tanaka T; Yamamoto A; Takasuka H
J Investig Med High Impact Case Rep; 2020; 8():2324709620966843. PubMed ID: 33078639
[TBL] [Abstract][Full Text] [Related]
5. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature.
Gao S; Zhou Y; Jin X; Lin Z; Zhong Y; Shen X
Surv Ophthalmol; 2019; 64(2):225-232. PubMed ID: 30321569
[TBL] [Abstract][Full Text] [Related]
6. Vitreoretinal lymphoma occurring after systemic chemotherapy for primary conjunctival diffuse large B cell lymphoma: A case report.
Niidome E; Usui Y; Takahashi R; Nagao T; Goto H
Medicine (Baltimore); 2021 Oct; 100(39):e27347. PubMed ID: 34596140
[TBL] [Abstract][Full Text] [Related]
7. Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.
Abu Samra K; Oray M; Ebrahimiadib N; Lee S; Anesi S; Foster CS
Ocul Immunol Inflamm; 2018; 26(3):347-352. PubMed ID: 27438792
[TBL] [Abstract][Full Text] [Related]
8. CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.
Liu S; Gu J; Zhang T; Ping B; Zhou M; Huang X; Jiang R; Xu G; Chang Q
Retina; 2021 Dec; 41(12):2596-2604. PubMed ID: 34173362
[TBL] [Abstract][Full Text] [Related]
9. Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?
Matsuo T; Tanaka T
J Clin Exp Hematop; 2019 Dec; 59(4):168-174. PubMed ID: 31611509
[TBL] [Abstract][Full Text] [Related]
10. Intraocular Relapse with Hypopyon and Retinal Infiltrates after Chemotherapy and Peripheral Blood Stem Cell Transplantation for Extranodal NK/T-Cell Lymphoma.
Matsuo T; Tanaka T; Ichimura K; Meguri Y
J Clin Exp Hematop; 2015; 55(3):157-61. PubMed ID: 26763364
[TBL] [Abstract][Full Text] [Related]
11. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
Chaput F; Amer R; Baglivo E; Touitou V; Kozyreff A; Bron D; Bodaghi B; LeHoang P; Bergstrom C; Grossniklaus HE; Chan CC; Pe'er J; Caspers LE
Ocul Immunol Inflamm; 2017 Oct; 25(5):639-648. PubMed ID: 27002464
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
[TBL] [Abstract][Full Text] [Related]
13. How we diagnose and treat vitreoretinal lymphoma.
Fend F; Ferreri AJ; Coupland SE
Br J Haematol; 2016 Jun; 173(5):680-92. PubMed ID: 27133587
[TBL] [Abstract][Full Text] [Related]
14. MACULAR HOLE FORMATION AFTER PARS PLANA VITRECTOMY FOR PRIMARY VITREORETINAL LYMPHOMA.
Haruta M; Taguchi C; Yamakawa R
Retin Cases Brief Rep; 2020; 14(3):243-246. PubMed ID: 29176526
[TBL] [Abstract][Full Text] [Related]
15. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
16. Development of Vitreoretinal Lymphoma in a Patient with Sarcoid Uveitis.
Wartique L; Jamilloux Y; De Parisot De Bernecourt A; Kodjikian L; Ghesquieres H; Ide C; Sève P
Ocul Immunol Inflamm; 2020 May; 28(4):647-650. PubMed ID: 31268740
[TBL] [Abstract][Full Text] [Related]
17. Primary Vitreoretinal Lymphoma in HIV Infection.
Steffen J; Coupland SE; Smith JR
Ocul Immunol Inflamm; 2021 Apr; 29(3):621-627. PubMed ID: 32453669
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Chang-Lin JE; Burke JA; Peng Q; Lin T; Orilla WC; Ghosn CR; Zhang KM; Kuppermann BD; Robinson MR; Whitcup SM; Welty DF
Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4605-9. PubMed ID: 21421864
[TBL] [Abstract][Full Text] [Related]
19. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma.
Ito T; Takeda A; Fujiwara K; Hasegawa E; Nakao S; Ohishi Y; Oda Y; Yoshikawa H; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):1029-1036. PubMed ID: 30868235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
